Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Centocor's Analysis Of Remicade Medicare Costs Relies On Low Dose

Executive Summary

A Centocor analysis comparing Medicare costs for Remicade to Immunex' Enbrel relies on an assumption that physicians would use the low dose of Remicade.

You may also be interested in...

Remicade Labeling Should Allow For Higher Dose Option, Arthritis Cmte. Says

Centocor Remicade labeling should indicate that some patients may benefit from a higher dosage of the drug, but should also emphasize the greater safety risks associated with higher dosing, members of the FDA Arthritis Drugs Advisory Committee suggested.

Immunex Novantrone For MS May Cost $5,107 Per Year, Lewin Study Finds

The estimated cost of Immunex' Novantrone for treatment of multiple sclerosis is $5,107 per year excluding the cost of cardiac monitoring, according to a Lewin Group analysis released March 14.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts